Aducanumab

Drug Profile

Aducanumab

Alternative Names: BART; BIIB 037; NI-10

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Neurimmune Therapeutics
  • Developer Biogen
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Alzheimer's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 08 Dec 2016 Interim efficacy and adverse events data from a phase Ib trial in Alzheimer's disease released by Biogen
  • 01 Sep 2016 Aducanumab receives Fast Track designation for Alzheimer's disease [IV,Infusion] (Early-stage disease) in USA
  • 23 Jul 2016 Pharmacodynamics data from a early research in Alzheimer's disease presented at the Alzheimer's Association International Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top